ECP

Planet Fitness To Celebrate Grand Opening Of New "Judgement Free" Club In Elizabethton, TN

Retrieved on: 
Tuesday, September 7, 2021

ELIZABETHTON, Tenn., Sept. 7, 2021 /PRNewswire/ -- Planet Fitness ,one of the largest and fastest-growing global franchisors and operators of fitness centers with more members than any other fitness brand, today announced the grand opening for its new club in Elizabethton on Wednesday, September 15.

Key Points: 
  • ELIZABETHTON, Tenn., Sept. 7, 2021 /PRNewswire/ -- Planet Fitness ,one of the largest and fastest-growing global franchisors and operators of fitness centers with more members than any other fitness brand, today announced the grand opening for its new club in Elizabethton on Wednesday, September 15.
  • The grand opening will kick off with a ribbon cutting ceremony at 1:00 p.m with the Planet Fitness team, representatives from the Elizabethton Carter County Chamber of Commerce and local officials.
  • Planet Fitness will also be donating $1,000 to the Boys & Girls Clubs of Elizabethton and Carter County (BGCECC) in celebration of the grand opening.
  • More than 95% of Planet Fitness stores are owned and operated by independent business men and women.

Mallinckrodt Presents Interim Results on Real World Use of Extracorporeal Photopheresis (ECP) in Heart Transplant Patients in a Late-Breaking Presentation at the 20th Congress of the European Society for Organ Transplantation (ESOT)

Retrieved on: 
Thursday, September 2, 2021
Patient, Neurology, Degenerative disease, Rheumatology, Risk, International Society for Heart and Lung Transplantation, Graft-versus-host disease, PR, Annual report, NYHA, Transplant, Antibody, U.S. Securities and Exchange Commission, Blood, Heart transplantation, AMR, Congress, Immunomodulation, T-cell lymphoma, Skin manifestations of sarcoidosis, ECP, SEC, CAV, CTCL, Autoimmunity, Hypotension, Investor relations, Safety, Education, Knowledge, Analgesic, Nephrology, Organ transplantation, Trial of the century, Research, Ajman Specialty General Hospital, Immunotherapy, ACR, Ophthalmology, European Society for Primary Immunodeficiencies, New York Heart Association Functional Classification, Surgery, International Society, Lung transplantation, Dietary supplement, Dentistry, Health insurance, Medical imaging, Pharmaceutical industry

DUBLIN, Sept. 2, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, announced today interim results1 from a retrospective, explorative, single-arm, pan-European multicenter study to evaluate the real world use of extracorporeal photopheresis (ECP) and therapy-related outcomes in heart transplant patients. The first results from the largest known study of ECP in heart transplantation patients were reported during a late-breaking oral presentation at the 20th Congress of the European Society for Organ Transplantation (ESOT) in Milan, Italy.

Key Points: 
  • The first results from the largest known study of ECP in heart transplantation patients were reported during a late-breaking oral presentation at the 20th Congress of the European Society for Organ Transplantation (ESOT) in Milan, Italy.
  • Of the 71 patient charts examined, 51 patients (72 percent) were no longer receiving ECP treatment and treatment was ongoing for 20 patients (28 percent).
  • The remaining 19 patients (40 percent) showed stable graft function at the end of ECP treatment.
  • The study relied on real world medical charts which could be missing data or may have used site-specific measurement schedules and procedures.

ECP, Inc. Wins Diamond for Appearance Protection Products and Gold for F&I Products in 2021 Dealers' Choice Awards. Launches industry first ECP Ultimate Plus® Diamond Ceramic with Graphene.

Retrieved on: 
Friday, August 27, 2021
Diamond, Industry, ECP, Dealer, Web Cartoonists' Choice Awards, Gold, CEO, Patent, Technology, Security (finance)

"ECP is committed to researching and developing best in class products that offer superior protection and has developed many industry firsts.

Key Points: 
  • "ECP is committed to researching and developing best in class products that offer superior protection and has developed many industry firsts.
  • We are excited to announce our new patent pending ECP Ultimate Plus with Diamond Ceramic and Graphene.
  • We are excited to bring this innovation to market," said Brian Feldman, Director of Optional Protection Products.
  • Founded in 1969, ECP, Inc.'s protection products have been sold on over 150 million vehicles.

Esperanza Capital Partners Announces New Energy Investment Platform

Retrieved on: 
Thursday, August 26, 2021
Professional Services, Other Energy, Other Professional Services, Oil, Gas, Energy, Finance, Industry, LLC, Gulf of Mexico, Vinson & Elkins, Acquisition, Partner, Agriculture, GOM, Cockrell, Emerging Capital Partners, Big Oil, ECP, LLP, Partnership, Willkie Farr & Gallagher, Security (finance)

Esperanza Capital Partners (ECP) is pleased to announce the formation of its inaugural energy investment platform, founded by Managing Partners David M. Dunwoody, Jr. and William H. Goodwin alongside investment firm Cockrell Interests, LLC (Cockrell).

Key Points: 
  • Esperanza Capital Partners (ECP) is pleased to announce the formation of its inaugural energy investment platform, founded by Managing Partners David M. Dunwoody, Jr. and William H. Goodwin alongside investment firm Cockrell Interests, LLC (Cockrell).
  • Armed with long-duration capital partners, a unique investment structure and a track record of safely building and operating a portfolio of offshore assets, ECP is positioned to pursue the diverse set of opportunities that exist in the offshore energy sector.
  • Prior to ECP, Mr. Dunwoody was Co-founder and President of EnVen Energy Corporation, an independent operator in the GOM, and Mr. Goodwin was a Partner at Millennial Energy Partners, an energy investment firm and direct asset manager.
  • Cockrell is a Houston-based, family-owned investment firm with 70 years of investment experience in asset classes including private equity, agriculture, real estate, venture capital, public equities, and credit.

HOYA Vision Care Welcomes Warren Modlin as Vice President, Technical Marketing

Retrieved on: 
Monday, August 23, 2021
Glasses, Oakley, LCD, Rx, AR, HDD, ECP, Multimedia, Information technology, Research and development, Technology, CIBA, Management, Telescopic sight

LEWISVILLE, Texas, Aug. 23, 2021 /PRNewswire/ -- Ophthalmic lens technology leader HOYA Vision Care announced today that Warren Modlin has joined the company as its Vice President of Technical Marketing. In his role, Modlin leads professional relations and innovation strategies for North America, in addition to representing the North American market and delivering on key global initiatives alongside Research & Development.

Key Points: 
  • LEWISVILLE, Texas, Aug. 23, 2021 /PRNewswire/ -- Ophthalmic lens technology leader HOYA Vision Care announced today that Warren Modlin has joined the company as its Vice President of Technical Marketing.
  • "I am excited to join a company that is equally dedicated to supporting its customers with innovative products and unparalleled service," said Modlin.
  • "We are very happy to welcome Warren to our global team of visionaries," said Eduardo Martins, President of HOYA Vision Care, North America.
  • For over 60 years, HOYA Vision Care has been a global leader in the eyeglass lens business.

Worldwide Photopheresis Products Industry to 2029 - Key Drivers, Challenges and Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 11, 2021
Biotechnology, Health, Medical Devices, Autoimmunity, Scleroderma, GVHD, T-cell lymphoma, US Foods, Incidence, ECP, Patient, Food, Atopic dermatitis, National Institute, NIEHS, Photopheresis, Death, Blood, CTL, Graft-versus-host disease, Lupus erythematosus, Research, Asia, National Institute of Environmental Health Sciences, Transplant, UVA, Autoimmune disease, Female, Crohn's disease, Degenerative disease, Population, Lichen planus, Government, Woman, Pharmaceutical industry, Vaccine

The US Food and Drug Administration has approved photopheresis, commonly known as extracorporeal photopheresis (ECP), for the treatment of cutaneous T-cell lymphoma.

Key Points: 
  • The US Food and Drug Administration has approved photopheresis, commonly known as extracorporeal photopheresis (ECP), for the treatment of cutaneous T-cell lymphoma.
  • This report covers all the quantitative aspects of the Photopheresis Products Market and also talks about its key drivers, the challenges it faces, the growth opportunities present in the market, and its future prospects.
  • A rise in the number of organ transplant patients is predicted to increase the demand for photopheresis products.
  • However, on other hand, due to the high cost of ECP therapy, the global market for photopheresis products may experience a slowdown.

Terra-Gen Closes Financing for First Phase of Edwards Sanborn Solar Storage Facility in California

Retrieved on: 
Monday, August 2, 2021
Energy, Renewable energy, Sustainable energy, Articles, Energy conversion, Solar power, Power engineering, Lithium-ion batteries

NEW YORK, Aug. 2, 2021 /PRNewswire/ -- Terra-Gen, LLC, a leading independent renewable energy provider, has completed financing on the initial phase of its Edwards Sanborn Solar Storage facility in Kern County, CA, a project that will produce clean energy for more than 158,000 homes and displace more than 307,000 tons of CO2 annually. The Edwards Sanborn Solar Storage facility is composed of 346 MWac (megawatts, alternating current) of solar modules and 1,501 MWh (megawatt hours) of battery storage. 

Key Points: 
  • The Edwards Sanborn Solar Storage facility is composed of 346 MWac (megawatts, alternating current) of solar modules and 1,501 MWh (megawatt hours) of battery storage.
  • "This financing allows us to complete the ongoing construction of the first phase of the Edwards Sanborn Solar Storage facility and help California meet its carbon reduction goals through the deployment of large-scale renewable energy," said Jim Pagano, Terra-Gen's CEO.
  • The Edwards Sanborn project is in Kern County on land leased from Edwards Air Force Base as well as on adjacent private land.
  • When complete, the near-term phases of the Edwards Sanborn Solar Storage franchise will comprise 760 MWac of solar and 2,445 MWh of energy storage and is expected to be the world's largest integrated solar powered battery storage project.

Mallinckrodt Announces 2021 Advancing Extracorporeal Photopheresis Immunomodulation Investigator Award

Retrieved on: 
Friday, March 19, 2021
Medicine, Blood, Light therapy, Photopheresis, Mallinckrodt, ECP, Health sciences

DUBLIN, March 19, 2021 /PRNewswire/ --A project that will analyze the immunomodulatory effects of extracorporeal photopheresis therapy (ECP) through innate cells has won Mallinckrodt plc's 2021 Advances in ImmunomodulatoryECPresearch award.

Key Points: 
  • DUBLIN, March 19, 2021 /PRNewswire/ --A project that will analyze the immunomodulatory effects of extracorporeal photopheresis therapy (ECP) through innate cells has won Mallinckrodt plc's 2021 Advances in ImmunomodulatoryECPresearch award.
  • Research funded from the inaugural investigator award, which was founded in 2018 to mark the 30th anniversary of Mallinckrodt's pioneering THERAKOS ECP ImmunomodulationTM,was also presented at this year's EBMT.
  • Congratulating the winning team, Romano added: "As a pioneer in ECP immunomodulation, Mallinckrodt is proud to support the work of those who continue to investigate this exciting field of medicine.
  • The 2022 Advancing ECP Immunomodulation Investigator Award will be open for entries in September.

Mallinckrodt Announces Launch of 2020 Award in Support of Advancing ECP Immunomodulation

Retrieved on: 
Tuesday, October 22, 2019
Medicine, Clinical medicine, Health, Mallinckrodt, Immunomodulation, Photopheresis, MNK, ECP

STAINES-UPON-THAMES, United Kingdom, Oct. 222019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, has announced that its 2020 Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award is open for entries.

Key Points: 
  • STAINES-UPON-THAMES, United Kingdom, Oct. 222019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, has announced that its 2020 Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award is open for entries.
  • The award, now in its third year, was developed by Mallinckrodt to mark 30 years of its pioneering THERAKOS ECP Immunomodulation.
  • The Investigator Award reflects the company's ongoing commitment to the science of immunomodulation through ECP and its therapeutic applications.
  • "As a pioneer in ECP immunomodulation, Mallinckrodt established the ECP Immunomodulation Investigator Awardto recognise the efforts of those working in this exciting field of medicine.

Mallinckrodt Announces 2019 Investigator Award for Pioneering Efforts in ECP Immunomodulation

Retrieved on: 
Tuesday, March 26, 2019
Medicine, Mallinckrodt, Immunomodulation, Photopheresis, MNK, ECP, Health

STAINES-UPON-THAMES, England, March 26, 2019 /PRNewswire/ --Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the recipient of 2019's Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award.

Key Points: 
  • STAINES-UPON-THAMES, England, March 26, 2019 /PRNewswire/ --Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the recipient of 2019's Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award.
  • Mallinckrodt developed the Investigator Award to mark 30 years of its pioneering THERAKOS ECP Immunomodulation.
  • The Investigator Award reflects the company's ongoing commitment to the science of immunomodulation through ECP and its therapeutic applications.
  • The 2020 Advancing ECP Immunomodulation Investigator Award will be open for entries in September 2019.